Search results
Results From The WOW.Com Content Network
Prochlorperazine is thought to exert its antipsychotic effects by blocking dopamine receptors. [29] Prochlorperazine is analogous to chlorpromazine; both of these agents antagonize dopaminergic D 2 receptors in various pathways of the central nervous system. This D 2 blockade results in antipsychotic, antiemetic and other effects.
In addition, factors such as rapid infusion, concurrent use of more than one drug known to prolong QT interval, diuretic treatment, electrolyte derangements (hypokalemia, hypomagnesemia, or hypocalcemia), advanced age, bradyarrhythmias, and female sex have all been shown to be risk factors for developing drug-induced QT prolongation. [2]
Prochlorperazine and desferrioxamine may also interact with chlorpromazine to produce transient metabolic encephalopathy. [ 5 ] Other drugs that prolong the QT interval, such as quinidine , verapamil , amiodarone , sotalol and methadone , may also interact with chlorpromazine to produce additive QT interval prolongation.
Research shows that diets that contain ultra-processed foods (like potato chips, candy, fast food, hot dogs, etc.) may be associated with more of a risk of immune dysregulation-linked diseases ...
Dopamine receptor flow chart. Dopamine receptors are all G protein–coupled receptors, and are divided into two classes based on which G-protein they are coupled to. [1] The D 1-like class of dopamine receptors is coupled to Gα s/olf and stimulates adenylate cyclase production, whereas the D 2-like class is coupled to Gα i/o and thus inhibits adenylate cyclase production.
A Healthier Heart. PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a review in the Journal of Endocrinology.Credit not just ...
The researchers found that these medications helped lower the risk of developing 42 different health conditions or outcomes, including dementia, cardiac arrest, and certain kinds of cancer. But ...
Amisulpride has been associated with QT prolongation. [7] [8] [9] Due to its greater ratio of brain to peripheral concentrations and much lower doses, N-methylamisulpride is expected to have reduced risk of QT prolongation in comparison. [9] [4] As of December 2023, N-methylamisulpride is in phase 2 clinical trials for schizophrenia. [1]